Dennis R. Leahy, MD, shares his POV on the value of making Lp(a) testing universal, not only to inform patients and their clinicians of the high CV risks, but to make way for potential treatments.

The evidence implicating high levels of lipoprotein(a), or Lp(a), as a risk predictor for heart attack, stroke, and other cardiovascular conditions has outpaced the science of what to do about the ...

A blood test that measures lipoprotein(a) [Lp(a)] has received breakthrough device designation from the US Food and Drug Administration. The Tina-quant Lp(a) RxDx assay, developed by Roche in ...

Researchers from University of California San Diego School of Medicine have found that testing for lipoprotein(a) - a genetic risk factor for heart disease - remains uncommon in the United States, ...

Roche has received the US Food and Drug Administration’s (FDA) breakthrough device designation for its Tina-quant lipoprotein Lp(a) RxDx assay, a diagnostic tool for cardiovascular disease risk. This ...

Anjali advises that specific nutrients could aid in the progressive reduction of Lp(a) levels When people think about cholesterol and heart health, they usually focus on total cholesterol and LDL ...

Some cardiologists say that certain people — such as those with a family history of premature heart disease — would benefit from having their lipoprotein(a) level checked, as well as their HDL and LDL ...

SAN CARLOS, Calif.--(BUSINESS WIRE)-- The Lipoprotein(a) Foundation was recently named a Top Nonprofit of 2019 by GreatNonprofits, the leading platform for community-sourced stories about nonprofits.

New York, July 04, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Low-Density Lipoprotein Test Global Market Report 2023" - https ...